The role of glucagon-like peptide-1 receptor agonists in non-alcoholic fatty liver disease
10.3760/cma.j.issn.1000-6699.2014.11.017
- VernacularTitle:胰升糖素样肽-1受体激动剂对非酒精性脂肪性肝病的影响
- Author:
Lixin GUO
- Publication Type:Journal Article
- Keywords:
Non-alcoholic fatty liver disease;
Glucagon-like peptide-1;
Diabetes mellitus,type 2;
Glucagon-like peptide-1 receptor agonists
- From:
Chinese Journal of Endocrinology and Metabolism
2014;30(11):1017-1020
- CountryChina
- Language:Chinese
-
Abstract:
Glucagon-like peptide-1 (GLP-1) receptor agonists are incretin-based drugs for type 2diabetes.In recent years,it has been proven in clinical practices that GLP-1 receptor agonists have protection effect beyond anti-hyperglycemic effects,such as improvement of non-alcoholic fatty liver disease (NAFLD).The cogent evaluation,understanding,and exploration of therapeutic effect and mechanism of GLP-1 receptor agonists in NAFLD are important.Besides,it would be of great significance to identify pathogenesis of diabetes,its correlation with NAFLD,and the development of new drugs.This article briefly reviews the therapeutic effect of GLP-1 receptor agonists on NAFLD.
